为探讨前列腺增生和前列腺癌的病因及发病机制，应用免疫组织化学SP法检测了14例正常前列腺、60例前列腺增生和33例前列腺癌组织中表皮生长因子受体（EGFR）和雄激素结合位点（ABS）的表达。结果显示，前列腺增生（90.0％）和前列腺癌（93．9％）组织中EGFR阳性表达率明显高于正常组织（57.1％）；前列腺癌中ABS的阳性率（90.9％）明显高于增牛（70．0％）和正常组织（64．3％），而增生组织中ABS强阳性率（43．3％）又明显高于正常组织（14．3％）。EGFR表达与肿瘤病理分级呈正相关，而与ABS表达无相关。EGFR与ABS表达在正常组织中呈负相关，增生组织中两者表达无相关，而癌变组织中两者表达呈正相关。提示EGFR和ABS异常表达及两者之间调控关系紊乱可能在前列腺增生和癌变的病因学中起重要作用。 To investigate the etiopathology and pathogenesis of benign prostatic hyperplasia and prostatic cancer, immunohistochemical SP method was used to detect the expression of epidermal growth factor receptor (EGFR) and androgen binding site in 14 cases of normal prostate, 60 cases of benign prostatic hyperplasia and 33 cases of prostatic carcinoma (ABS) expression. The results showed that the positive expression rate of EGFR in benign prostatic hyperplasia (90.0%) and prostate cancer (93.9%) was significantly higher than that in normal tissue (57.1%). The positive rate of ABS in prostate cancer was significantly higher (70.0%) and normal tissues (64.3%), while the positive rate of ABS in hyperplastic tissues was significantly higher than that in normal tissues (43.3%). EGFR expression was positively correlated with tumor pathological grade, but not with ABS expression. EGFR and ABS expression in normal tissue was negatively correlated, no correlation between the expression of both the proliferation of tissue, while the cancerous tissue was positively correlated. Suggest that abnormal expression of EGFR and ABS and the relationship between the two disorders may play an important role in the pathogenesis of benign prostatic hyperplasia and cancer.